Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

PRIMARY OBJECTIVES:

I. To determine temporal changes in leukemic cell nuclear factor of kappa light chain
enhancer of B-cells 1 (NF-kB) activity when salicylate (choline magnesium trisalicylate) is
administered to patients with acute myeloid leukemia (AML) during induction chemotherapy.

II. To determine toxicities associated with administration of salicylate in the setting of
induction chemotherapy.

III. To determine if salicylate alters the expression of NF-kB-regulated genes in AML cells.

IV. To determine if NF-kB modulation by salicylate alters AML chemotherapy drug efflux.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive choline magnesium trisalicylate orally (PO) every 8 hours on days
0-7, idarubicin intravenously (IV) on days 1-3, and cytarabine IV continuously on days 1-7.

ARM II: Patients receive idarubicin IV on days 1-3 and cytarabine IV continuously on days
1-7.

In both arms, treatment continues in the absence of disease progression or unacceptable
toxicity.

After completion of study treatment, patients are followed up periodically.

Inclusion Criteria:

- Patients must have a diagnosis of non-M3 AML (patients with M3 subtype are excluded);
determination of the presence of cytogenetic abnormalities will be by standard
cytogenetics +/- fluorescent-in-situ (FISH) studies; additional molecular analyses for
nucleophosmin (NPM) mutation and fms-related tyrosine kinase 3 (flt3) internal tandem
duplication will be obtained as a part of standard care by institutional procedures

- Leukemic blast count > 1500/mm^3 of peripheral blood

- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =<
3

- Total bilirubin < 2 times the institutional upper limit of normal (ULN)

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) < 3
times the institutional ULN

- Serum creatinine < 1.5 times the institutional ULN

- Multi gated acquisition scan (MUGA) or echocardiogram with left ventricular ejection
fraction (LVEF) > 50%

- Women of childbearing potential must have a negative pregnancy test

- No uncontrolled psychiatric illness that the principal investigator feels will
compromise obtaining informed consent from a patient

- Patient must be informed of the investigational nature of this study and must give
written informed consent in accordance with institutional and federal guidelines;
patients who do not provide informed consent will not be eligible for the study

Exclusion Criteria:

- Any coexisting medical condition or medications precluding full compliance with any of
the arms of the study

- Allergies to any investigational drugs and/or to the chemotherapeutic agents

- Allergies to any non-steroidal anti-inflammatory drugs (NSAIDs)/salicylates (e.g.,
aspirin)

- Endoscopically documented upper or lower gastrointestinal (GI) related hemorrhage
within last 6 months; also, patients with a clinical diagnosis of GI bleeding
requiring blood transfusions will be excluded